Blennow, Kaj
Shaw, Leslie M.
Stomrud, Erik
Mattsson, Niklas
Toledo, Jon B.
Buck, Katharina
Wahl, Simone
Eichenlaub, Udo
Lifke, Valeria
Simon, Maryline
Trojanowski, John Q. http://orcid.org/0000-0002-9239-8794
Hansson, Oskar
Funding for this research was provided by:
Roche Diagnostics
Article History
Received: 29 August 2019
Accepted: 31 October 2019
First Online: 13 December 2019
Competing interests
: K.B. served as a consultant or at advisory boards for Alzheon, BioArctic, Roche Diagnostics, Eli Lilly, Fujirebio Europe, Merck, Novartis and IBL International. His research team has received funds for research from Roche Diagnostics. He is the co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Venture-based platform company at the University of Gothenburg. L.M.S. received research support from NIH/NIA, ADNI (AG024904) and UPenn ADCC Biomarker Core (AG010124), MJFox Foundation for PD research, Roche, Lilly; provides QC oversight for Roche Elecsys CSF AD biomarker immunoassays for ADNI; and is a consultant for Roche, Lilly, Novartis. E.S., N.M., J.B.T. and J.Q.T. declare that they have no conflict of interest. S.W., U.E., V.L., M.S., and K.Bu. are Roche employees. O.H. acquired research support (for the institution) from Roche, GE Healthcare, Biogen, AVID Radiopharmaceuticals, Fujirebio and Euroimmun. In the past 2 years, he has received consultancy/speaker fees (paid to the institution) from Lilly, Roche and Fujirebio.